BioVentrix Announces Pivotal ALIVE Trial Resumes with First Patients Treated with LIVE Therapy Since COVID-19 Pause
San Ramon, Calif. – September 2, 2020 – BioVentrix, Inc., [...]
BioVentrix Announces Appointment of Accredited Public Company Director, Raymond W. Cohen, to its Board of Directors
SAN RAMON, Calif. – August 12, 2020 – BioVentrix, Inc., [...]
Innovatives kathetergestütztes Verfahren, LIVE“ zur Behandlung der Herzschwäche nach Herzinfarkt
Erstmals in Deutschland vorgestelltDie anhaltende infarktbedingte Herzschwäche besitzt weltweit eine [...]
FierceMedTech Names BioVentrix as One of Its “Fierce 15” Companies of 2019
SAN RAMON, Calif. — March 9, 2020 — BioVentrix, Inc., [...]
Dr. Ralph Stephan von Bardeleben als Co-Principal Investigator für die randomisierte klinische Studie REVIVE-HF von BioVentrix bekanntgegeben
San Ramon, Kalifornien – 4. März 2020 – BioVentrix, Inc., [...]
BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial
REVIVE-HF seeks to demonstrate superiority of the Revivent TC System [...]
BioVentrix Announces Gregg Stone, MD, as Co-Principal Investigator for ALIVE Pivotal Trial of Transcatheter Device for Heart Failure
SAN RAMON, Calif. – February 18, 2020 – BioVentrix, Inc., [...]
Innovative Herzinfarkttherapie: Angebot in Deutschland wächst
Für Herzinfarkt-Patienten ist die innovative LIVE™-Therapie (Less Invasive Ventricular Enhancement) [...]
BioVentrix Receives 2020 NUB Reimbursement Status 1 Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
San Ramon, CA – February 6, 2020 – Bioventrix, Inc., [...]
Europäische Kommission verlängert die CE-Zulassung für das BioVentrix Revivent TC System der LIVETM Therapie (Less Invasive Ventricular Enhancement)
San Ramon, Kalifornien – 22. Januar 2020 – BioVentrix, Inc., [...]
